One year before a potential launch, Inex Pharmaceuticals Corp. found a North American partner - Enzon Pharmaceuticals Inc. - for its cancer drug Onco TCS. (BioWorld Today)

ILEX Oncology Inc.'s drug eflornithine (DFMO) failed to reach statistical significance in a Phase III trial with superficial bladder cancer patients, resulting in the company's decision to discontinue development. (BioWorld Today)